A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Around 59,000 individuals are shockingly killed by the rabies virus each year, and several of them are children. Some victims, particularly children, discover they have been exposed after it is too late.
At the Nagoya University in Japan, scientists have come up with a new chemical-only process that might signify an essential discovery in making tailored mRNA vaccines for a range of diseases and enable the low-cost making of mRNA in large quantities.
Clustered regularly interspaced short palindromic repeats (CRISPR) and their accompanying protein, CRISPR-associated protein 9 (Cas9), several years ago, made international news as a game-changing genome editing system.
Many people believe tuberculosis (TB) is a disease of the past. Nonetheless, it claims over a million lives each year. Furthermore, the problem is escalating as Mycobacterium tuberculosis—the pathogen that causes tuberculosis develops resistance to the antibiotics used to treat the disease.
Two RNA binding proteins have been discovered to be the key to a greater immune reaction to influenza in mice, according to researchers at the Babraham Institute.
In latest years, messenger RNA—the DNA’s close relative in the complex process of turning a string of genetic blueprints into a properly functioning organism—has gotten a lot of attention in the scientific and medical community.
Sartorius Octet® becomes the only brand to offer the two leading label-free technologies: BLI and SPR.
The dysfunction of memory CD8 + T cell can not be reverted by successful clearance of hepatitis C virus (HCV) after direct-acting antivirals (DAA) therapy, increasing the risk of reinfection with HCV.
The virus that causes COVID-19, SARS-CoV-2, can directly infect a specialized type of kidney cell.
A vaccine for hepatitis C has eluded scientists for more than 30 years, for several reasons. For one, the virus that causes the disease comes in many genetic forms, complicating the creation of a widely effective vaccine.
Cancer has been the leading cause of death in Japan over the past 40 years. Despite the rise in patients due to the aging population, progresses in diagnosis and treatment are leading to higher survival rates.
Researchers at the Okinawa Institute of Science and Technology Graduate University have revealed how poxviruses build their scaffold - a temporary protein coat that forms and disappears as the virus matures.
People who were infected with SARS-CoV-2 before being vaccinated generate an immune response more specific to fighting viral infections, and produce a broader antibody response, than do people whose only protection is the vaccine, according to researchers at the University of Washington School of Medicine.
According to research published in eLife, researchers have developed a pipeline for detecting, prioritizing, and testing potential tumor antigens for the rapid development of cancer vaccines.
In Central and South America, predatory blood-sucking bugs transmit the causative agent of the widely prevalent Chagas disease.
Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed a novel method of delivering drugs into human cells using large biological molecules, by first encasing them in a protein-based microdroplet.
Physicists, chemists and immunologists at McMaster University have teamed up to modify red blood cells to transport viral agents which can safely trigger the immune system to protect the body against SARS-CoV-2, creating a promising new vehicle for vaccine delivery.
Briefly blocking a key molecule when administering the only approved vaccine for tuberculosis vastly improves long-term protection against the devastating disease in mice, researchers from Texas Biomedical Research Institute report this week in the Journal of Immunology.
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is one of the most deadly diseases in the swine industry.
The SARS-CoV-2 virus is continuously evolving and structural changes to the virus may impact the efficacy of antibody therapies and vaccines.